JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.73 3.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.98

Max

11.89

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M -20M
Pardavimai	5.9M 40M
Pelno marža	-49.569
Darbuotojai	184
EBITDA	16M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+95.35% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	432M 1.2B
Ankstesnė atidarymo kaina	8.38
Ankstesnė uždarymo kaina	11.73

Naujienos nuotaikos

By Acuity

50%

144 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-09 17:25; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

2026-02-09 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

2026-02-09 23:43; UTC

Rinkos pokalbiai

Gold Falls on Possible Technical Correction -- Market Talk

2026-02-09 23:14; UTC

Rinkos pokalbiai

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

2026-02-09 22:29; UTC

Rinkos pokalbiai

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

2026-02-09 22:19; UTC

Rinkos pokalbiai

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

2026-02-09 22:08; UTC

Rinkos pokalbiai

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

2026-02-09 22:01; UTC

Uždarbis

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

2026-02-09 21:59; UTC

Uždarbis

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

2026-02-09 21:59; UTC

Uždarbis

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

2026-02-09 21:58; UTC

Uždarbis

Friedman Industries 3Q Sales $168M >FRD

2026-02-09 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-09 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-09 21:48; UTC

Uždarbis

Friedman Industries 3Q EPS 43c >FRD

2026-02-09 21:17; UTC

Uždarbis

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

2026-02-09 21:13; UTC

Rinkos pokalbiai

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

2026-02-09 21:04; UTC

Uždarbis

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

2026-02-09 20:30; UTC

Rinkos pokalbiai

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

2026-02-09 20:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

2026-02-09 19:42; UTC

Rinkos pokalbiai

Japan's Yield Curve Expected to Flatten -- Market Talk

2026-02-09 19:31; UTC

Rinkos pokalbiai

Nike Seen Regaining Relevance With Consumers -- Market Talk

2026-02-09 19:27; UTC

Rinkos pokalbiai

Gold Climbs Back Over $5,000/oz -- Market Talk

2026-02-09 19:05; UTC

Rinkos pokalbiai

Nike Returns to List of Hottest Brands -- Market Talk

2026-02-09 18:19; UTC

Rinkos pokalbiai

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

2026-02-09 17:41; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

2026-02-09 17:31; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

2026-02-09 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-09 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-09 17:17; UTC

Rinkos pokalbiai

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

2026-02-09 17:16; UTC

Uždarbis

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

95.35% į viršų

12 mėnesių prognozė

Vidutinis 22.29 USD 95.35%

Aukščiausias 29 USD

Žemiausias 16 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

144 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.